Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ846,5849,5-0,47
KB838,5839,50,84
PKN65,1965,22,32
Msft421,58421,750,08
Nokia3,28853,2915-1,11
IBM190,36190,9-0,02
Mercedes-Benz Group AG73,9373,940,56
PFE27,7727,78-0,04
28.03.2024 13:12:32
Indexy online
AD Index online
select
AD Index online
 

  • 27.03.2024
Amgen Inc (AMGN.O, NASDAQ Cons)
Závěr k 27.3.2024 Změna (%) Změna (USD) Objem obchodů (ks)
286,30 1,61 4,53 2 256 315
Premarket28.03.2024 13:06:02
Poslední obchod Nákup / Prodej Změna (%) Změna (USD) Objem obchodů (ks)
287,25 287,12 288,14 0,33 0,95 1 461
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 28.03.2024
Popis společnosti
Obecné informace
Název společnostiAmgen Inc
TickerAMGN
Kmenové akcie:Ordinary Shares
RICAMGN.O
ISIN-
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.12.2023
Počet zaměstnanců k 31.12.2023 26 700
Akcie v oběhu k 09.02.2024 535 918 901
MěnaUSD
Konstituent indexůS&P 500
Dow Industry
Kontaktní informace
UliceOne Amgen Center Drive
MěstoTHOUSAND OAKS
PSČ91320
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon18 054 471 000
Fax18054471010

Business Summary: Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Amgen Inc revenues increased 7% to $28.19B. Net income increased 3% to $6.72B. Revenues reflect TEPEZZA segment increase from $0K to $448M, Prolia segment increase of 12% to $4.05B, US segment increase of 9% to $19.27B, ROW segment increase of 8% to $7.64B. Net income was partially offset by Interest expense, net increase from $1.41B to $2.88B (expense), Selling.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Pharmaceuticals (NEC)
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Research and Development in Biotechnology
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Biological Product (except Diagnostic) Manufacturing
NAICS1997Pharmaceutical Preparation Manufacturing
SICBiological Prod's Not Diagnostic
SICCommercial Physical Research
SICBiological Prod's Not Diagnostic
SICPharmaceutical Preparations



  • Poslední aktualizace: 28.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, President, Chief Executive OfficerRobert Bradway6001.01.201310.04.2007
Chief Financial Officer, Executive Vice PresidentPeter Griffith6401.01.202023.10.2019
Executive Vice President, Chief Technology OfficerDavid Reese6018.12.202326.07.2018
Executive Vice President, Research and Development, and Chief Scientific OfficerJames Bradner5018.12.202318.12.2023
Executive Vice President, General Counsel, SecretaryJonathan Graham62
Executive Vice President - Human ResourcesLori Johnston-01.01.2016
Executive Vice President - Global Commercial OperationsMurdo Gordon5603.09.201803.09.2018
Executive Vice President - OperationsEsteban Santos55
Senior Vice President, Chief Compliance OfficerNancy Grygiel5501.01.2020
Senior Vice President - Business DevelopmentRachna Khosla5001.01.2021